Datasets:
SKT27182
/
NER_processed_data

Dataset card Data Studio Files
xet
Community
1
id
stringlengths
11
11
tags
stringlengths
10
777
text
stringlengths
2
1.5k
dataset_num
int64
1
3
tokens
list
ner_tags
list
NCT02471911
21:24:chronic_disease,26:44:chronic_disease,46:64:chronic_disease
Patients with known HIV, active hepatitis B, active hepatitis C
3
[ "Patients", "with", "known", "HIV", ",", "active", "hepatitis", "B", ",", "active", "hepatitis", "C" ]
[ 0, 0, 0, 2, 0, 2, 2, 2, 0, 0, 0, 0 ]
NCT02577731
14:32:chronic_disease
Blunt and/or penetrating trauma patient
3
[ "Blunt", "and/or", "penetrating", "trauma", "patient" ]
[ 0, 0, 2, 2, 0 ]
NCT02004275
1:14:chronic_disease
Liver disease with history of positive serology
3
[ "Liver", "disease", "with", "history", "of", "positive", "serology" ]
[ 2, 2, 0, 0, 0, 0, 0 ]
NCT02133885
1:25:chronic_disease
unstable angina pectoris,
3
[ "unstable", "angina", "pectoris", "," ]
[ 2, 2, 2, 0 ]
NCT01950351
11:37:chronic_disease,42:72:chronic_disease,86:115:treatment,125:146:treatment
diagnosed connective tissue disorder, or congenital coagulation defects (patients on medical therapy with Coumadin or other blood thinning agents are eligible for participation)
3
[ "diagnosed", "connective", "tissue", "disorder", ",", "or", "congenital", "coagulation", "defects", "(", "patients", "on", "medical", "therapy", "with", "Coumadin", "or", "other", "blood", "thinning", "agents", "are", "eligible", "for", "participation", ")" ]
[ 0, 2, 2, 2, 0, 0, 2, 2, 2, 0, 0, 0, 1, 1, 1, 1, 0, 0, 1, 1, 1, 0, 0, 0, 0, 0 ]
NCT03135171
1:44:treatment,
Immunization with a live/attenuated vaccine within 30 days of enrollment
3
[ "Immunization", "with", "a", "live/attenuated", "vaccine", "within", "30", "days", "of", "enrollment" ]
[ 1, 1, 1, 1, 1, 0, 0, 0, 0, 0 ]
NCT02685605
12:19:cancer,,
History of cancers or other comorbidities that limit life expectancy to less than five years
3
[ "History", "of", "cancers", "or", "other", "comorbidities", "that", "limit", "life", "expectancy", "to", "less", "than", "five", "years" ]
[ 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
NCT02566304
35:45:cancer,62:73:cancer,99:108:treatment
Patients with evidence of another malignancy, exclusive of a skin cancer that requires only local treatment, should not be enrolled on this protocol
3
[ "Patients", "with", "evidence", "of", "another", "malignancy", ",", "exclusive", "of", "a", "skin", "cancer", "that", "requires", "only", "local", "treatment", ",", "should", "not", "be", "enrolled", "on", "this", "protocol" ]
[ 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 3, 3, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0 ]
NCT02048371
,,19:35:cancer
Age ≥ 5 years for Rhabdomyosarcoma cohorts
3
[ "Age", "≥", "5", "years", "for", "Rhabdomyosarcoma", "cohorts" ]
[ 0, 0, 0, 0, 0, 3, 0 ]
NCT02516696
28:65:treatment,73:84:treatment,88:103:treatment,125:142:treatment
Patients may have received prior adjuvant antiresorptive therapy (i.e., pamidronate or zoledronic acid) as routine care, or radiation therapy as palliation for pain and/or spinal cord compression
3
[ "Patients", "may", "have", "received", "prior", "adjuvant", "antiresorptive", "therapy", "(", "i.e.", ",", "pamidronate", "or", "zoledronic", "acid", ")", "as", "routine", "care", ",", "or", "radiation", "therapy", "as", "palliation", "for", "pain", "and/or", "spinal", "cord", "compression" ]
[ 0, 0, 0, 0, 1, 1, 1, 1, 0, 0, 0, 1, 0, 1, 1, 0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0 ]
NCT02007239
7:32:chronic_disease
Known active herpetic infection
3
[ "Known", "active", "herpetic", "infection" ]
[ 0, 2, 2, 2 ]
NCT02252432
1:16:chronic_disease
Thyroid disease
3
[ "Thyroid", "disease" ]
[ 2, 2 ]
NCT02484404
20:30:cancer,32:43:cancer,45:79:cancer
Patients must have metastatic, progressive, castrate resistant prostate cancer (mCRPC)
3
[ "Patients", "must", "have", "metastatic", ",", "progressive", ",", "castrate", "resistant", "prostate", "cancer", "(", "mCRPC", ")" ]
[ 0, 0, 0, 3, 0, 3, 0, 3, 3, 3, 3, 0, 0, 0 ]
NCT02549937
56:71:treatment
Subject is currently receiving or intending to receive anti-coagulants for therapeutic purposes
3
[ "Subject", "is", "currently", "receiving", "or", "intending", "to", "receive", "anti-coagulants", "for", "therapeutic", "purposes" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0 ]
NCT02517307
1:19:chronic_disease,28:36:chronic_disease,40:65:chronic_disease
endocrine disorder such as diabetes or untreated thyroid disease
3
[ "endocrine", "disorder", "such", "as", "diabetes", "or", "untreated", "thyroid", "disease" ]
[ 2, 2, 0, 0, 2, 0, 2, 2, 2 ]
NCT03060564
10:35:treatment
previous acromioclavicular surgery
3
[ "previous", "acromioclavicular", "surgery" ]
[ 0, 1, 1 ]
NCT01306019
29:51:chronic_disease
Any current or pre-existing hematologic malignancy
3
[ "Any", "current", "or", "pre-existing", "hematologic", "malignancy" ]
[ 0, 0, 0, 0, 2, 2 ]
NCT02519322
120:130:treatment
A known or underlying medical condition that, in the opinion of the Investigator, could make the administration of the study drug hazardous to the subject or could adversely affect the ability of the subject to comply with or tolerate the study
3
[ "A", "known", "or", "underlying", "medical", "condition", "that", ",", "in", "the", "opinion", "of", "the", "Investigator", ",", "could", "make", "the", "administration", "of", "the", "study", "drug", "hazardous", "to", "the", "subject", "or", "could", "adversely", "affect", "the", "ability", "of", "the", "subject", "to", "comply", "with", "or", "tolerate", "the", "study" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
NCT03154476
15:37:treatment
Subjects with implantable pacemakers
3
[ "Subjects", "with", "implantable", "pacemakers" ]
[ 0, 0, 1, 1 ]
NCT02995330
8:30:chronic_disease,59:62:chronic_disease,63:67:chronic_disease,71:87:chronic_disease
Active uncontrolled infection, including known history of HIV/AIDS or hepatitis B or C
3
[ "Active", "uncontrolled", "infection", ",", "including", "known", "history", "of", "HIV/AIDS", "or", "hepatitis", "B", "or", "C" ]
[ 0, 2, 2, 0, 0, 0, 0, 0, 2, 0, 2, 2, 2, 2 ]
NCT02564796
1:23:chronic_disease,48:53:treatment,126:149:treatment,151:188:treatment
Cyanotic heart disease who have had a surgical shunt or a catheterization intervention that is equivalent to a shunt (patent ductus arteriosus stent, right ventricular outflow tract stent)
3
[ "Cyanotic", "heart", "disease", "who", "have", "had", "a", "surgical", "shunt", "or", "a", "catheterization", "intervention", "that", "is", "equivalent", "to", "a", "shunt", "(", "patent", "ductus", "arteriosus", "stent", ",", "right", "ventricular", "outflow", "tract", "stent", ")" ]
[ 2, 2, 2, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 0, 1, 1, 1, 1, 1, 0 ]
NCT02095808
37:53:allergy_name
Patients with a contraindication to MRI examinations
3
[ "Patients", "with", "a", "contraindication", "to", "MRI", "examinations" ]
[ 0, 0, 0, 0, 0, 4, 4 ]
NCT02568267
23:42:treatment,44:48:treatment,53:67:treatment,89:95:cancer
excluding approved or investigational Trk, ROS1, or ALK inhibitors in patients who have tumors that harbor those respective gene rearrangements
3
[ "excluding", "approved", "or", "investigational", "Trk", ",", "ROS1", ",", "or", "ALK", "inhibitors", "in", "patients", "who", "have", "tumors", "that", "harbor", "those", "respective", "gene", "rearrangements" ]
[ 0, 0, 0, 1, 1, 0, 1, 0, 0, 1, 1, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0 ]
NCT02543983
1:48:treatment,
Treatment with any other concomitant medication not allowed within 5 (Omega) half-lives prior to study Phase II
3
[ "Treatment", "with", "any", "other", "concomitant", "medication", "not", "allowed", "within", "5", "(", "Omega", ")", "half-lives", "prior", "to", "study", "Phase", "II" ]
[ 1, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
NCT02374021
,33:43:treatment
Current use of >10mg per day of prednisone
3
[ "Current", "use", "of", ">", "10mg", "per", "day", "of", "prednisone" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 1 ]
NCT02105766
1:19:chronic_disease,,,,
Sickle hepatopathy defined as EITHER ferritin >1000mcg/L OR direct bilirubin >0.4 mg/dL at baseline
3
[ "Sickle", "hepatopathy", "defined", "as", "EITHER", "ferritin", ">", "1000mcg/L", "OR", "direct", "bilirubin", ">", "0.4", "mg/dL", "at", "baseline" ]
[ 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
NCT02304458
1:19:treatment
Stem cell infusion
3
[ "Stem", "cell", "infusion" ]
[ 1, 1, 1 ]
NCT01389024
33:36:treatment,,,
All screening procedures except MRI can be completed between 9 and 12 months of age, with the exception of the MRI, for which the child must have reached the age of 12 months
3
[ "All", "screening", "procedures", "except", "MRI", "can", "be", "completed", "between", "9", "and", "12", "months", "of", "age", ",", "with", "the", "exception", "of", "the", "MRI", ",", "for", "which", "the", "child", "must", "have", "reached", "the", "age", "of", "12", "months" ]
[ 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
NCT01966367
28:50:treatment,,,141:162:treatment,163:188:treatment
Patients who have received prior hematocrit (HCT) within three months of enrollment for reduced intensity regimen and within six months for myeloablative regimen/reduced toxicity regimens
3
[ "Patients", "who", "have", "received", "prior", "hematocrit", "(", "HCT", ")", "within", "three", "months", "of", "enrollment", "for", "reduced", "intensity", "regimen", "and", "within", "six", "months", "for", "myeloablative", "regimen/reduced", "toxicity", "regimens" ]
[ 0, 0, 0, 0, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 0, 0, 0, 0, 0, 1, 1, 0, 0 ]
NCT02323880
,57:83:treatment
at least 42 days must have elapsed if other substantial bone marrow (BM) radiation
3
[ "at", "least", "42", "days", "must", "have", "elapsed", "if", "other", "substantial", "bone", "marrow", "(", "BM", ")", "radiation" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 1, 0, 0 ]
NCT03114319
32:48:treatment
Must have progressed following standard therapy, or for whom, in the opinion of the Investigator
3
[ "Must", "have", "progressed", "following", "standard", "therapy", ",", "or", "for", "whom", ",", "in", "the", "opinion", "of", "the", "Investigator" ]
[ 0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
NCT02588326
,96:115:treatment,117:135:treatment,140:148:treatment
Exposure to any medication/food that alters the CYP 3A4 activity within last 2 weeks (e.g. any grapefruit products, azole anti-fungals, or rifampin)
3
[ "Exposure", "to", "any", "medication/food", "that", "alters", "the", "CYP", "3A4", "activity", "within", "last", "2", "weeks", "(", "e.g", ".", "any", "grapefruit", "products", ",", "azole", "anti-fungals", ",", "or", "rifampin", ")" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0, 1, 1, 0, 0, 1, 0 ]
NCT01730794
17:39:treatment
Need to provide controlled ventilation
3
[ "Need", "to", "provide", "controlled", "ventilation" ]
[ 0, 0, 0, 1, 1 ]
NCT01415752
15:18:chronic_disease,,
No history of CD4 prior to or at the time of lymphoma diagnosis < 300 cells/mm³
3
[ "No", "history", "of", "CD4", "prior", "to", "or", "at", "the", "time", "of", "lymphoma", "diagnosis", "<", "300", "cells/mm³" ]
[ 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
NCT03080142
29:46:allergy_name
Patients with an allergy to local anesthetics
3
[ "Patients", "with", "an", "allergy", "to", "local", "anesthetics" ]
[ 0, 0, 0, 0, 0, 4, 4 ]
NCT03153410
48:71:allergy_name
History of severe hypersensitivity reaction to any monoclonal antibody
3
[ "History", "of", "severe", "hypersensitivity", "reaction", "to", "any", "monoclonal", "antibody" ]
[ 0, 0, 0, 0, 0, 0, 4, 4, 4 ]
NCT02091999
76:105:allergy_name
Known sensitivity to any of the ingredients of the investigational product enfortumab vedotin (ASG-22CE)
3
[ "Known", "sensitivity", "to", "any", "of", "the", "ingredients", "of", "the", "investigational", "product", "enfortumab", "vedotin", "(", "ASG-22CE", ")" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 4, 4, 0, 0 ]
NCT01280994
25:58:treatment,74:79:treatment,,99:102:treatment
Subject has received an investigational medicinal product (not including 129Xe) within 30 days of MRI
3
[ "Subject", "has", "received", "an", "investigational", "medicinal", "product", "(", "not", "including", "129Xe", ")", "within", "30", "days", "of", "MRI" ]
[ 0, 0, 0, 0, 1, 1, 1, 0, 0, 0, 1, 0, 0, 0, 0, 0, 1 ]
NCT01912612
21:28:chronic_disease
Significant risk of suicide based on the Investigator's judgment
3
[ "Significant", "risk", "of", "suicide", "based", "on", "the", "Investigator", "'s", "judgment" ]
[ 0, 0, 0, 2, 0, 0, 0, 0, 0, 0 ]
NCT02577731
10:37:treatment
Previous bone marrow transplantation
3
[ "Previous", "bone", "marrow", "transplantation" ]
[ 0, 1, 1, 1 ]
NCT02554903
31:55:chronic_disease,,
Documented moderate to severe restrictive lung disease defined as: total lung capacity < 60% of predicted value
3
[ "Documented", "moderate", "to", "severe", "restrictive", "lung", "disease", "defined", "as", ":", "total", "lung", "capacity", "<", "60", "%", "of", "predicted", "value" ]
[ 0, 0, 0, 0, 2, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
NCT02423863
12:32:treatment
History of active immunotherapy in the previous month
3
[ "History", "of", "active", "immunotherapy", "in", "the", "previous", "month" ]
[ 0, 0, 1, 1, 0, 0, 0, 0 ]
NCT02213289
4:7:chronic_disease,
No CVA within 6 months
3
[ "No", "CVA", "within", "6", "months" ]
[ 0, 2, 0, 0, 0 ]
NCT02638454
1:15:treatment
ACE inhibitors
3
[ "ACE", "inhibitors" ]
[ 1, 1 ]
NCT02946658
17:37:treatment,
Exposure to any investigational drug or procedure with 1 month prior to study entry or enrollment in concurrent study which may interfere with interpretation of study results
3
[ "Exposure", "to", "any", "investigational", "drug", "or", "procedure", "with", "1", "month", "prior", "to", "study", "entry", "or", "enrollment", "in", "concurrent", "study", "which", "may", "interfere", "with", "interpretation", "of", "study", "results" ]
[ 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
NCT02349035
52:62:treatment
Significant new injury that would prevent use of a prosthesis: The ability to consistently wear a prosthesis and perform activities of daily living and specific performance tasks is necessary to evaluate the relative benefits of the interventions
3
[ "Significant", "new", "injury", "that", "would", "prevent", "use", "of", "a", "prosthesis", ":", "The", "ability", "to", "consistently", "wear", "a", "prosthesis", "and", "perform", "activities", "of", "daily", "living", "and", "specific", "performance", "tasks", "is", "necessary", "to", "evaluate", "the", "relative", "benefits", "of", "the", "interventions" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
NCT02524379
,105:119:treatment
Breast-feeding women who do not agree to stop breast-feeding during and for 7 days following the end of oral glyburide administration
3
[ "Breast-feeding", "women", "who", "do", "not", "agree", "to", "stop", "breast-feeding", "during", "and", "for", "7", "days", "following", "the", "end", "of", "oral", "glyburide", "administration" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0 ]
NCT02334579
17:29:treatment
Prior high-dose radiotherapy to the prostate or lower pelvis
3
[ "Prior", "high-dose", "radiotherapy", "to", "the", "prostate", "or", "lower", "pelvis" ]
[ 0, 0, 1, 0, 0, 0, 0, 0, 0 ]
NCT01415752
35:57:treatment
Must be willing to take effective antiretroviral therapy, if indicated
3
[ "Must", "be", "willing", "to", "take", "effective", "antiretroviral", "therapy", ",", "if", "indicated" ]
[ 0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0 ]
NCT02474667
1:27:chronic_disease,,71:83:treatment,87:106:treatment,,144:159:treatment
Oligo-anuric renal failure (less than 200 mL of UO per day) requiring hemodialysis or peritoneal dialysis initiated at least 3 months prior to transplantation
3
[ "Oligo-anuric", "renal", "failure", "(", "less", "than", "200", "mL", "of", "UO", "per", "day", ")", "requiring", "hemodialysis", "or", "peritoneal", "dialysis", "initiated", "at", "least", "3", "months", "prior", "to", "transplantation" ]
[ 2, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 1 ]
NCT02692651
,44:54:treatment,59:68:treatment,96:99:chronic_disease,
Patients receiving ≥ 1 high or medium risk antibiotic for treatment of an infection other than CDI, for an anticipated duration of ≥ 5 days from the time of enrollment
3
[ "Patients", "receiving", "≥", "1", "high", "or", "medium", "risk", "antibiotic", "for", "treatment", "of", "an", "infection", "other", "than", "CDI", ",", "for", "an", "anticipated", "duration", "of", "≥", "5", "days", "from", "the", "time", "of", "enrollment" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 1, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
NCT01976169
24:75:cancer
All subjects must have recurrent or metastatic HER2-positive breast cancer
3
[ "All", "subjects", "must", "have", "recurrent", "or", "metastatic", "HER2-positive", "breast", "cancer" ]
[ 0, 0, 0, 0, 3, 3, 3, 3, 3, 3 ]
NCT02431897
37:47:treatment
Physically able to apply/insert the study drug
3
[ "Physically", "able", "to", "apply/insert", "the", "study", "drug" ]
[ 0, 0, 0, 0, 0, 1, 1 ]
NCT02533674
1:38:cancer
Gastrointestinal stromal tumor (GIST)
3
[ "Gastrointestinal", "stromal", "tumor", "(", "GIST", ")" ]
[ 3, 3, 3, 3, 0, 0 ]
NCT02347891
17:25:treatment,
Discontinuation IS agent < 3 months prior to Screening
3
[ "Discontinuation", "IS", "agent", "<", "3", "months", "prior", "to", "Screening" ]
[ 0, 1, 1, 0, 0, 0, 0, 0, 0 ]
NCT02964182
1:14:treatment
nitroglycerin
3
[ "nitroglycerin" ]
[ 1 ]
NCT02494869
11:30:chronic_disease
Suspected dissecting aneurysm
3
[ "Suspected", "dissecting", "aneurysm" ]
[ 0, 2, 2 ]
NCT02391987
23:32:allergy_name,34:46:allergy_name,48:56:allergy_name,58:65:allergy_name
Known skin allergy to adhesives (hydrocolloid, silicone, acrylic)
3
[ "Known", "skin", "allergy", "to", "adhesives", "(", "hydrocolloid", ",", "silicone", ",", "acrylic", ")" ]
[ 0, 0, 0, 0, 4, 0, 4, 0, 4, 0, 4, 0 ]
NCT03034564
24:49:chronic_disease
Significant history of Gastro Intestinal disease that may interfere with absorption
3
[ "Significant", "history", "of", "Gastro", "Intestinal", "disease", "that", "may", "interfere", "with", "absorption" ]
[ 0, 0, 0, 2, 2, 2, 0, 0, 0, 0, 0 ]
NCT02796391
1:20:treatment
Erlotinib (Tarceva)
3
[ "Erlotinib", "(", "Tarceva", ")" ]
[ 1, 1, 0, 0 ]
NCT03021486
14:29:cancer
Diagnosis of advanced cancer (defined as locally advanced, metastatic recurrent, or incurable disease)
3
[ "Diagnosis", "of", "advanced", "cancer", "(", "defined", "as", "locally", "advanced", ",", "metastatic", "recurrent", ",", "or", "incurable", "disease", ")" ]
[ 0, 0, 3, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
NCT01925573
29:42:treatment,49:63:treatment,65:80:treatment,84:96:treatment,99:110:treatment,126:142:chronic_disease,,171:181:treatment,239:247:treatment,264:286:treatment,
Patients who have undergone major surgery (e.g. intra-thoracic, intra-abdominal or intra-pelvic), open biopsy or significant traumatic injury ≤ 4 weeks prior to starting study drug, or patients who have had minor procedures, percutaneous biopsies or placement of vascular access device ≤ 1 week prior to starting study drug, or who have not recovered from side effects of such procedure or injury
3
[ "Patients", "who", "have", "undergone", "major", "surgery", "(", "e.g", ".", "intra-thoracic", ",", "intra-abdominal", "or", "intra-pelvic", ")", ",", "open", "biopsy", "or", "significant", "traumatic", "injury", "≤", "4", "weeks", "prior", "to", "starting", "study", "drug", ",", "or", "patients", "who", "have", "had", "minor", "procedures", ",", "percutaneous", "biopsies", "or", "placement", "of", "vascular", "access", "device", "≤", "1", "week", "prior", "to", "starting", "study", "drug", ",", "or", "who", "have", "not", "recovered", "from", "side", "effects", "of", "such", "procedure", "or", "injury" ]
[ 0, 0, 0, 0, 1, 1, 0, 0, 0, 1, 0, 1, 0, 1, 0, 0, 1, 1, 0, 0, 2, 2, 0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
NCT01989585
35:45:treatment,64:70:treatment,77:105:treatment,116:142:treatment,188:198:treatment,251:308:treatment,317:334:treatment,343:353:treatment,355:362:treatment,368:378:treatment,388:423:treatment,483:494:treatment,528:584:treatment,,621:645:treatment
Preclinical studies indicate that navitoclax is metabolized by CYP3A4, is a moderate inhibitor of CYP2C8, and is a strong inhibitor of CYP2C9; there is also evidence of interactions with dabrafenib; therefore, caution should be exercised when dosing navitoclax concurrently with CYP2C8 and CYP2C9 substrates; common CYP2C8 substrates include paclitaxel, statins, and glitazones, whereas CYP2C9 substrates include phenytoin; when possible, investigators should switch to alternative medications or monitor the patients closely; CYP3A inhibitors such as ketoconazole and clarithromycin are not allowed 7 days prior to the first dose of navitoclax or during navitoclax administration
3
[ "Preclinical", "studies", "indicate", "that", "navitoclax", "is", "metabolized", "by", "CYP3A4", ",", "is", "a", "moderate", "inhibitor", "of", "CYP2C8", ",", "and", "is", "a", "strong", "inhibitor", "of", "CYP2C9", ";", "there", "is", "also", "evidence", "of", "interactions", "with", "dabrafenib", ";", "therefore", ",", "caution", "should", "be", "exercised", "when", "dosing", "navitoclax", "concurrently", "with", "CYP2C8", "and", "CYP2C9", "substrates", ";", "common", "CYP2C8", "substrates", "include", "paclitaxel", ",", "statins", ",", "and", "glitazones", ",", "whereas", "CYP2C9", "substrates", "include", "phenytoin", ";", "when", "possible", ",", "investigators", "should", "switch", "to", "alternative", "medications", "or", "monitor", "the", "patients", "closely", ";", "CYP3A", "inhibitors", "such", "as", "ketoconazole", "and", "clarithromycin", "are", "not", "allowed", "7", "days", "prior", "to", "the", "first", "dose", "of", "navitoclax", "or", "during", "navitoclax", "administration" ]
[ 0, 0, 0, 0, 1, 1, 1, 1, 1, 1, 1, 0, 1, 1, 1, 1, 1, 0, 0, 0, 1, 1, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 1, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 1, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 1, 0, 0, 0, 0 ]
NCT01631617
19:45:chronic_disease
Family history of toxic epidermal necrolysis
3
[ "Family", "history", "of", "toxic", "epidermal", "necrolysis" ]
[ 0, 0, 0, 2, 2, 2 ]
NCT02905591
1:9:treatment
warfarin
3
[ "warfarin" ]
[ 1 ]
NCT02912572
59:77:cancer
This test is now done routinely for every newly diagnosed endometrial cancer patient in most centers in the US
3
[ "This", "test", "is", "now", "done", "routinely", "for", "every", "newly", "diagnosed", "endometrial", "cancer", "patient", "in", "most", "centers", "in", "the", "US" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 3, 0, 0, 0, 0, 0, 0, 0 ]
NCT02484404
52:69:cancer
Histologically or cytologically confirmed advanced colorectal cancer
3
[ "Histologically", "or", "cytologically", "confirmed", "advanced", "colorectal", "cancer" ]
[ 0, 0, 0, 0, 0, 3, 3 ]
NCT02960113
9:32:chronic_disease,34:43:chronic_disease,48:60:chronic_disease
Current urinary tract infection, pneumonia, or otitis media
3
[ "Current", "urinary", "tract", "infection", ",", "pneumonia", ",", "or", "otitis", "media" ]
[ 0, 2, 2, 2, 0, 2, 0, 0, 2, 2 ]
NCT02446457
26:45:cancer,,93:117:treatment,138:156:treatment,180:185:cancer
with histologic proof of follicular lymphoma grade 1, 2, or 3a relapsing after at least two prior systemic therapies, which must include CAR T cell therapy or histologic proof of DLBCL relapsing after at least two prior systemic therapies, which must include CAR T cell therapy
3
[ "with", "histologic", "proof", "of", "follicular", "lymphoma", "grade", "1", ",", "2", ",", "or", "3a", "relapsing", "after", "at", "least", "two", "prior", "systemic", "therapies", ",", "which", "must", "include", "CAR", "T", "cell", "therapy", "or", "histologic", "proof", "of", "DLBCL", "relapsing", "after", "at", "least", "two", "prior", "systemic", "therapies", ",", "which", "must", "include", "CAR", "T", "cell", "therapy" ]
[ 0, 0, 0, 0, 3, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 0, 0, 0, 0, 1, 1, 1, 1, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
NCT03011307
48:63:treatment
Currently Workman's Comp litigation related to hip replacement
3
[ "Currently", "Workman", "'s", "Comp", "litigation", "related", "to", "hip", "replacement" ]
[ 0, 0, 0, 0, 0, 0, 0, 1, 1 ]
NCT02627495
210:227:treatment
Presence of the following contraindication to transcranial direct current stimulation Ferromagnetic metal in the head (e.g., plates or pins, bullets, shrapnel) Implanted head electronic medical devices (e.g., cochlear implants)
3
[ "Presence", "of", "the", "following", "contraindication", "to", "transcranial", "direct", "current", "stimulation", "Ferromagnetic", "metal", "in", "the", "head", "(", "e.g.", ",", "plates", "or", "pins", ",", "bullets", ",", "shrapnel", ")", "Implanted", "head", "electronic", "medical", "devices", "(", "e.g.", ",", "cochlear", "implants", ")" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0 ]
NCT01822522
,115:137:treatment,139:151:treatment,153:177:treatment,182:204:treatment
women of childbearing potential include women who have experienced menarche and who have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or are not postmenopausal
3
[ "women", "of", "childbearing", "potential", "include", "women", "who", "have", "experienced", "menarche", "and", "who", "have", "not", "undergone", "successful", "surgical", "sterilization", "(", "hysterectomy", ",", "bilateral", "tubal", "ligation", ",", "or", "bilateral", "oophorectomy", ")", "or", "are", "not", "postmenopausal" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0, 1, 0, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
NCT02465268
28:40:allergy_name,42:48:allergy_name,52:54:allergy_name
Prior allergic reaction to temozolomide, GM-CSF or Td
3
[ "Prior", "allergic", "reaction", "to", "temozolomide", ",", "GM-CSF", "or", "Td" ]
[ 0, 0, 0, 0, 4, 0, 4, 0, 4 ]
NCT01360606
10:22:treatment
No prior radiotherapy to the upper abdomen
3
[ "No", "prior", "radiotherapy", "to", "the", "upper", "abdomen" ]
[ 0, 0, 1, 0, 0, 0, 0 ]
NCT02423525
25:37:cancer
Previous or concomitant malignancies at other sites
3
[ "Previous", "or", "concomitant", "malignancies", "at", "other", "sites" ]
[ 0, 0, 0, 3, 0, 0, 0 ]
NCT02950233
18:42:treatment
Planned elective VATS pulmonary lobectomy
3
[ "Planned", "elective", "VATS", "pulmonary", "lobectomy" ]
[ 0, 0, 1, 1, 1 ]
NCT01773694
10:28:treatment,32:57:treatment,63:87:treatment
standard excisional surgery or Mohs micrographic surgery with immediate reconstruction
3
[ "standard", "excisional", "surgery", "or", "Mohs", "micrographic", "surgery", "with", "immediate", "reconstruction" ]
[ 0, 1, 1, 0, 1, 1, 1, 0, 1, 1 ]
NCT01130077
5:43:treatment
Any investigational therapeutic medication
3
[ "Any", "investigational", "therapeutic", "medication" ]
[ 0, 1, 1, 1 ]
NCT03059355
1:27:chronic_disease
Advanced pulmonary disease
3
[ "Advanced", "pulmonary", "disease" ]
[ 2, 2, 2 ]
NCT01280994
52:55:treatment
Subject does not fit into 129Xe vest coil used for MRI
3
[ "Subject", "does", "not", "fit", "into", "129Xe", "vest", "coil", "used", "for", "MRI" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1 ]
NCT02650206
1:14:cancer
MEN2 Syndrome
3
[ "MEN2", "Syndrome" ]
[ 3, 3 ]
NCT01851369
31:43:cancer
Phase II only: No other prior malignancies are allowed
3
[ "Phase", "II", "only", ":", "No", "other", "prior", "malignancies", "are", "allowed" ]
[ 0, 0, 0, 0, 0, 0, 0, 3, 0, 0 ]
NCT03037879
1:16:chronic_disease
Vision impaired
3
[ "Vision", "impaired" ]
[ 2, 2 ]
NCT01829958
31:63:treatment
patients being treated with a single agent monoclonal antibody
3
[ "patients", "being", "treated", "with", "a", "single", "agent", "monoclonal", "antibody" ]
[ 0, 0, 0, 0, 0, 1, 1, 1, 1 ]
NCT02310399
24:36:chronic_disease
Group 1: Prelinguistic hearing loss
3
[ "Group", "1", ":", "Prelinguistic", "hearing", "loss" ]
[ 0, 0, 0, 0, 2, 2 ]
NCT02578901
29:46:chronic_disease
Known inherited or acquired bleeding disorder
3
[ "Known", "inherited", "or", "acquired", "bleeding", "disorder" ]
[ 0, 0, 0, 0, 2, 2 ]
NCT02516241
1:17:cancer,21:44:chronic_disease,94:102:treatment,,146:161:treatment,196:212:cancer,241:244:treatment
Brain metastases or spinal cord compression unless the patient's condition is stable and off steroids for at least 14 days prior to the start of study treatment. Patients with suspected or known brain metastases at screening should have an MRI (preferred)/CT, preferably with IV contrast to access baseline disease status
3
[ "Brain", "metastases", "or", "spinal", "cord", "compression", "unless", "the", "patient", "'s", "condition", "is", "stable", "and", "off", "steroids", "for", "at", "least", "14", "days", "prior", "to", "the", "start", "of", "study", "treatment", ".", "Patients", "with", "suspected", "or", "known", "brain", "metastases", "at", "screening", "should", "have", "an", "MRI", "(", "preferred", ")", "/CT", ",", "preferably", "with", "IV", "contrast", "to", "access", "baseline", "disease", "status" ]
[ 3, 3, 0, 2, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 3, 3, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
NCT01703949
16:35:treatment
Intolerance to brentuximab vedotin
3
[ "Intolerance", "to", "brentuximab", "vedotin" ]
[ 0, 0, 1, 1 ]
NCT03122691
11:33:treatment,35:62:treatment,64:84:treatment,89:99:treatment,
Use of an Over-the-Counter (OTC), systemic or topical drug(s), herbal supplement(s), or vitamin(s) within 14 days of experimental sessions; which, in the opinion of the investigator or sponsor, will interfere with the study result or the safety of the subject
3
[ "Use", "of", "an", "Over-the-Counter", "(", "OTC", ")", ",", "systemic", "or", "topical", "drug", "(", "s", ")", ",", "herbal", "supplement", "(", "s", ")", ",", "or", "vitamin", "(", "s", ")", "within", "14", "days", "of", "experimental", "sessions", ";", "which", ",", "in", "the", "opinion", "of", "the", "investigator", "or", "sponsor", ",", "will", "interfere", "with", "the", "study", "result", "or", "the", "safety", "of", "the", "subject" ]
[ 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1 ]
NCT02262806
35:73:treatment
Documented metabolic benefit from prior or current metreleptin treatment
3
[ "Documented", "metabolic", "benefit", "from", "prior", "or", "current", "metreleptin", "treatment" ]
[ 0, 0, 0, 0, 1, 1, 1, 1, 1 ]
NCT02359253
1:8:chronic_disease
Apraxia
3
[ "Apraxia" ]
[ 2 ]
NCT02501096
1:17:chronic_disease,8:17:chronic_disease,43:61:treatment
Active infection (any infection requiring systemic treatment)
3
[ "Active", "infection", "(", "any", "infection", "requiring", "systemic", "treatment", ")" ]
[ 2, 2, 0, 0, 0, 0, 1, 1, 0 ]
NCT01500551
25:28:chronic_disease
Pediatric subjects with JIA
3
[ "Pediatric", "subjects", "with", "JIA" ]
[ 0, 0, 0, 2 ]
NCT02506192
1:13:chronic_disease
Pericarditis
3
[ "Pericarditis" ]
[ 2 ]
NCT01570816
1:19:chronic_disease
cardiac arrythmias
3
[ "cardiac", "arrythmias" ]
[ 2, 2 ]
NCT02171104
14:23:chronic_disease,25:31:chronic_disease,35:51:chronic_disease,62:65:chronic_disease,77:93:chronic_disease,99:110:chronic_disease,
Uncontrolled bacterial, fungal or viral infections including HIV (including active infection with Aspergillus or other mold within 30 days)
3
[ "Uncontrolled", "bacterial", ",", "fungal", "or", "viral", "infections", "including", "HIV", "(", "including", "active", "infection", "with", "Aspergillus", "or", "other", "mold", "within", "30", "days", ")" ]
[ 0, 2, 0, 2, 0, 2, 2, 0, 2, 0, 0, 2, 2, 0, 2, 0, 0, 0, 0, 0, 0, 0 ]
NCT02319369
14:60:treatment,,97:105:treatment,113:148:treatment,205:209:chronic_disease,218:234:treatment,,,374:410:treatment
Has received Hematopoietic Stem Cell Transplantation (HSCT) within 60 days of the first dose of DS-3032b, is on immunosuppressive therapy post-HSCT at the time of screening, or has clinically significant GVHD (use of topical steroids for ongoing skin GVHD will be permitted). Has a washout period of ≥ 2 weeks or at least 4 half-lives (whichever is longer) from their last systemic immunosuppressive treatment for GVHD
3
[ "Has", "received", "Hematopoietic", "Stem", "Cell", "Transplantation", "(", "HSCT", ")", "within", "60", "days", "of", "the", "first", "dose", "of", "DS-3032b", ",", "is", "on", "immunosuppressive", "therapy", "post-HSCT", "at", "the", "time", "of", "screening", ",", "or", "has", "clinically", "significant", "GVHD", "(", "use", "of", "topical", "steroids", "for", "ongoing", "skin", "GVHD", "will", "be", "permitted", ")", ".", "Has", "a", "washout", "period", "of", "≥", "2", "weeks", "or", "at", "least", "4", "half-lives", "(", "whichever", "is", "longer", ")", "from", "their", "last", "systemic", "immunosuppressive", "treatment", "for", "GVHD" ]
[ 0, 0, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 0, 0 ]
NCT01896999
6:32:chronic_disease
have primary refractory disease
3
[ "have", "primary", "refractory", "disease" ]
[ 0, 2, 2, 2 ]
NCT03104699
12:32:treatment,
use of any investigational drug within 28 days before start of trial treatment
3
[ "use", "of", "any", "investigational", "drug", "within", "28", "days", "before", "start", "of", "trial", "treatment" ]
[ 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0 ]
NCT03058679
55:76:treatment,78:97:treatment,99:126:treatment,128:147:treatment,151:162:treatment,
Start or change*** dose of anti-TNF agents (including infliximab (Remicade), adalimumab (Humira), certolizumab pegol (Cimzia), golimumab (Simponi) or ustekinumab within 8 weeks prior to screening
3
[ "Start", "or", "change", "*", "*", "*", "dose", "of", "anti-TNF", "agents", "(", "including", "infliximab", "(", "Remicade", ")", ",", "adalimumab", "(", "Humira", ")", ",", "certolizumab", "pegol", "(", "Cimzia", ")", ",", "golimumab", "(", "Simponi", ")", "or", "ustekinumab", "within", "8", "weeks", "prior", "to", "screening" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 1, 1, 0, 0, 0, 1, 1, 1, 0, 0, 0, 1, 1, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0 ]